Trial Outcomes & Findings for Cardiac Surgery Neuroprotection Study in Elders (NCT NCT01561378)

NCT ID: NCT01561378

Last Updated: 2021-11-10

Results Overview

Assessed using a battery of cognitive tests which test the following four domains: 1) executive function, 2) verbal memory, 3) attention and concentration, 4) language. Cognitive testing will be performed at the following time points: baseline (1-2 weeks prior to surgery) and 6 weeks after discharge.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

22 participants

Primary outcome timeframe

6-weeks

Results posted on

2021-11-10

Participant Flow

Participant milestones

Participant milestones
Measure
Insulin
Aspart Insulin 40 IU intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first Aspart insulin: 40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first) Intranasal mucosal atomizer device: Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
Normal Saline
Normal saline (0.9% sodium chloride solution) intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first Normal saline: 200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first) Intranasal mucosal atomizer device: Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
Overall Study
STARTED
11
11
Overall Study
COMPLETED
11
11
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Cardiac Surgery Neuroprotection Study in Elders

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 6-weeks

Population: The PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available

Assessed using a battery of cognitive tests which test the following four domains: 1) executive function, 2) verbal memory, 3) attention and concentration, 4) language. Cognitive testing will be performed at the following time points: baseline (1-2 weeks prior to surgery) and 6 weeks after discharge.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 7 days

Population: The PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available

Assessed using the Richmond Agitation Sedation Scale (RASS) and Confusion Assessment Method-ICU (CAM-ICU)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 7 days, 6 weeks

Population: The PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 14 days

Population: The PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 14 days

Population: The PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 30-day, 90-day

Population: The PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 1 to 90 days

Population: The PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 1 to 90 days

Population: The PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available

Outcome measures

Outcome data not reported

Adverse Events

Insulin

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Normal Saline

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Daniel Ceusters

Montefiore Medical Center

Phone: 718-920-2956

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place